Zoetis UK brought a quarterly canine osteoarthritis monoclonal antibody to Great Britain on September 24, 2026, giving practitioners a subcutaneous option that holds pain relief for up to three months from a single injection.

The product, Lenivia (izenivetmab injection), targets nerve growth factor (NGF) and binds a different site on the molecule than established anti-NGF antibodies already in veterinary use, according to the company's announcement. Clinical improvement appeared by Day 7 of the pivotal European field study and persisted through the three-month dosing interval.

What does the launch change at the exam table?

Practitioners in Great Britain now have an additional anti-NGF monoclonal antibody for canine OA, this one dosed every three months. Published estimates cited in the release put the prevalence of osteoarthritis pain in dogs at nearly 40%. Because OA worsens with age, sustained control matters more as the companion-animal population lives longer.

Tim Burgess, General Manager of Zoetis UK, framed the longer dosing interval as a way to help owners maintain consistent treatment for a condition requiring ongoing care. Quarterly visits also let the clinic recheck pain severity, mobility, body weight, and treatment response at every administration, he added.

How does izenivetmab work?

The molecule intercepts pain signaling at NGF rather than damping inflammation alone, distinguishing its mechanism from NSAIDs and other conventional analgesics. Zoetis positions Lenivia as differentiating itself within the anti-NGF class by binding a separate NGF epitope. The release reports no head-to-head efficacy or safety comparisons with competitor antibodies.

What does the clinical evidence show?

The company says it built Lenivia across approximately ten years of research and development. The pivotal European field study ran for nine months and demonstrated sustained reductions in OA pain throughout the dosing interval. The release does not disclose sample size, enrollment criteria, or adverse-event rates; prescribing veterinarians are directed to the Summary of Product Characteristics (SPC) for the complete dataset.

Where does Lenivia fit in a comprehensive OA plan?

Quarterly anti-NGF injections sit alongside, not in place of, the multi-modal approach most internists and surgeons already use. The release reminds clinicians that weight management, controlled exercise, rehabilitation, nutritional support, environmental modifications, and adjunctive analgesics remain core components of care. Long-term success still depends on regular re-evaluation and individualized adjustments for each patient.

What regulatory and prescribing notes apply?

Lenivia's prescribing and safety information lives in the Summary of Product Characteristics, which carries the binding indications, contraindications, precautions, and adverse-event reporting procedures for Great Britain. The release does not specify the product's regulatory status outside the country, and veterinarians elsewhere should consult their national authority for current authorization.

What should practices do next?

Clinics that manage chronic OA cases can audit which canine patients currently receive injectable analgesics and identify candidates suited to a longer dosing interval. Stocking plans, client communication scripts, and pricing structures may need updating before availability extends across the country. Zoetis said it will support veterinary teams as the rollout widens through Great Britain.

The addition of a differently targeted anti-NGF monoclonal antibody with quarterly dosing gives clinicians another lever for chronic canine pain management, though real-world adherence data and direct comparisons with established products will determine whether the convenience advantage translates into measurable welfare gains for the aging dog population.